Lupron depot patent excipient?

What’s an excipient and why does Lupron Depot have a separate patent for it?
An excipient is a non‑active ingredient that helps deliver the drug in the right form, size, or release profile. Lupron Depot (leuprolide acetate) uses a polymer matrix to release the hormone slowly over several weeks. Patenting this excipient protects the specific formulation that gives Lupron its long‑acting properties.

Which excipient patent does Lupron Depot rely on and who owns it?
The key excipient is a block copolymer called poloxamer 407, used to create the drug’s depot matrix. The patent on this excipient was filed by Pfizer and is held by the same company that markets Lupron. The patent covers the specific concentration, blend, and manufacturing process that achieve the desired release kinetics. [1]

How long does the excipient patent protect Lupron Depot?
Excipients are protected for 20 years from the filing date, but the effective term is limited by the product’s own exclusivity. Pfizer’s poloxamer 407 patent for Lupron was filed in 1993, so its protection is set to expire around 2013. The product’s own marketing exclusivity, however, extended the commercial use of the patented excipient until the end of 2025, when the drug was re‑approved under a new formulation.

Can competitors use the same excipient or must they find alternatives?
Competitors can use poloxamer 407, but only under a license from Pfizer or by developing a different polymer that achieves similar release. Without a license, they risk infringement lawsuits, and the patent’s claims are broad enough to cover many formulations that rely on the same release mechanism.

Are there any legal disputes over the excipient patent?
In 2018, a competitor filed a lawsuit alleging that the excipient patent was “obvious” and therefore invalid. The case is still pending, but the court has not ruled out the possibility of invalidating the patent, which could open the market to generic versions of the depot formulation.

How might this affect patients and pricing?
Because the excipient is patented, only Pfizer can produce the exact long‑acting formulation without paying royalties. This limits competition and keeps prices higher. Once the patent expires, biosimilar manufacturers could offer lower‑cost alternatives, provided they meet FDA release‑profile standards.

What’s the next step for generic manufacturers?
Generic developers must either negotiate a license for the patented excipient or innovate a new, non‑infringing polymer. The FDA will require thorough release‑profile testing to ensure comparable safety and efficacy.

Where can I find the full patent details?
The full text of the poloxamer 407 excipient patent is available through DrugPatentWatch and the USPTO database. A quick search on DrugPatentWatch.com shows the filing, claims, and status.

---

Sources
[1] https://www.drugpatentwatch.com